

DO WE STILL NEED GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS?

TREBAMO LI JOŠ UVIJEK GLUKOKORTIKOIDE U REUMATOIDNOM ARTRITISU I SISTEMSKOM ERITEMSKOM LUPUSU?

Gyorgy Nagy^{1,2,3}

¹*National Institute of Locomotor Diseases and Disabilities, Budapest, Hungary*

²*Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary*

³*Heart and Vascular Center, Semmelweis University, Budapest, Hungary*

The therapeutic landscape of both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) significantly evolved recently. Glucocorticoids (GCs) are well-established medications in both conditions, however major concerns are the risk of long-term adverse events and the difficulties in tapering GCs. The main reasons to support GCs use are the ability to rapidly suppress inflammation while waiting for the full effect of conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and targeted therapies. Real-world data suggest that glucocorticoid overtreatment is an increasingly recognized problem. At the same time, recommendations for the management of both diseases suggest minimizing glucocorticoids (GCs). Thus, whether GCs should be used in the management of RA and SLE is still a matter of debate. The presentation will provide an overview regarding the risks and benefits of GC treatment if RA and SLE.

Keywords: glucocorticoids, rheumatoid arthritis, systemic lupus erythematosus

E-mail of the main author: gyorgyngy@gmail.com

Conflict of interest statement: The authors declare no conflict of interest.